Worg Pharmaceuticals, a Chinese clinical-stage biopharmaceutical firm with a focus on immunotherapies, has secured “several hundreds of millions of yuan” ($14 million) in a funding round participated by local investment firm Tsing Song Capital.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com